<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451139</url>
  </required_header>
  <id_info>
    <org_study_id>AITM0107</org_study_id>
    <nct_id>NCT00451139</nct_id>
  </id_info>
  <brief_title>Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jimma University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jimma University</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the potential side-effects of artemether /&#xD;
      lumefantrine and other antimalarials on the auditory function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Artemisinin based combination therapies (ACT) currently are the most promising treatment&#xD;
      options for uncomplicated falciparum malaria. There have been controversial reports about&#xD;
      possible ototoxicity of artemether / lumefantrine (Coartem®) from retrospective studies. In&#xD;
      this investigation treatment of uncomplicated malaria with artemether / lumefantrine,&#xD;
      quinine, where side-effects on hearing are known, or atovaquone / proguanil, where no such&#xD;
      effects have been reported, are compared. Auditoy function is examined (Auditory Brainstem&#xD;
      Response, Pure-tone Audiometry, Otoacustic Emissions) before treatment, after 7, 28, and, for&#xD;
      determination of irreversibility, after 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Malaria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artemether/lumefantrine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quinine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atovaquone/proguanil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged above 5 years&#xD;
&#xD;
          -  Uncomplicated falciparum malaria&#xD;
&#xD;
          -  Axillary Temperature ≥37,5°C or history of fever within the previous 24 hours&#xD;
&#xD;
          -  Ability to tolerate oral therapy&#xD;
&#xD;
          -  Informed consent by the patient or by parent/guardian for children&#xD;
&#xD;
          -  Residence in study area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hearing deficits&#xD;
&#xD;
          -  Adequate anti-malarial treatment within the previous 7 days&#xD;
&#xD;
          -  Mixed infection&#xD;
&#xD;
          -  Danger signs and signs of severe malaria as defined by the WHO&#xD;
&#xD;
          -  Presence of severe underlying disease (cardiac, renal, hepatic diseases, malnutrition,&#xD;
             known HIV infection)&#xD;
&#xD;
          -  Concomitant disease masking assessment of response&#xD;
&#xD;
          -  History of allergy or intolerance against study medications&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nebreed Fesseaha, MD, Dean</last_name>
    <role>Study Chair</role>
    <affiliation>Facuty of Medical Sciences Jimma University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jimma University Hospital</name>
      <address>
        <city>Jimma</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <last_update_submitted>March 22, 2007</last_update_submitted>
  <last_update_submitted_qc>March 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Quinine</mesh_term>
    <mesh_term>Atovaquone</mesh_term>
    <mesh_term>Proguanil</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
    <mesh_term>Atovaquone, proguanil drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

